"Trade Margin Rationalisation offers a middle path between price control and market freedom in pharmaceuticals." Critically examine this with reference to non-scheduled anti-cancer drugs.

Trade Margin Rationalisation (TMR) caps the mark-up that distributors and retailers add above the manufacturer's price. NPPA applied it to 137 non-scheduled anti-cancer drugs from 9 November 2026 [1]. It is a real middle path, but an incomplete one.

Why TMR is a middle path

• Reaches the unregulated segment: non-scheduled drugs make up about 82% of the market. Their only control is a 10% cap on yearly price increases. Discounts of 20–60% on MRP show that trade margins are inflated [2].
• Leaves the maker's price alone: MRP falls without putting the drug under a ceiling price. Market freedom at the manufacturing stage stays [1].
• Shared enforcement: State Drug Controllers monitor prices and file Action Taken Reports. Patients can report overcharging on Pharma Sahi Daam. Violators face overcharging proceedings under DPCO, 2013 [1].
• Follows global practice: WHO's 2020 guideline lists regulating mark-ups along the supply chain as a pricing policy [4].

Why the middle path is incomplete

• Launch price is untouched: WHO's technical report found that cancer medicine pricing has failed health and economic needs [5]. The price to stockist (PTS) is not made public, so nobody can check whether the MRP is fair [3].
• Weak legal footing: DPCO allows margin caps only for a limited period [3]. There is no timeline for a permanent framework [2].
• Gaps in monitoring: NPPA's data leaves out hospital and e-commerce sales [2], which is where many cancer drugs are bought. Online drug platforms also have no price check [3].
• Weak deterrence: Rs 8,526 crore (85%) of overcharging demands is unrecovered, and 15 of 48 NPPA posts are vacant [2].
• Prices creep back up: even after regulation, stent prices rose 29–44% between 2017 and 2024 [3].

Way forward

• Amend DPCO to make TMR permanent, with a fixed deadline [2][3].
• Publish PTS and widen data coverage to hospitals and online sellers [2][3].
• Use cost-based pricing where mark-ups are abnormal [2]. Set up a fast-track system to recover overcharging dues.

TMR lowers what patients pay while keeping manufacturers free to set their own prices, so it is a sensible compromise. To turn this one-off order into a lasting middle path, India needs permanent legal backing, open supply-chain prices and stronger enforcement. That would serve the Article 47 duty to improve public health and SDG 3.8 on affordable medicines.